| Document |
Document Title |
|
WO/1992/004030A1 |
A stock solution comprising an aqueous suspension containing 1 to 2 g/ml of sucralfate particles with a mean diameter of 50 Al or less, which is used for producing sucralfate preparations; and a process for producing said stock solution ...
|
|
WO/1992/003453A1 |
A sulfated alkyl oligosaccharide prepared by substituting the hydroxyl group at the 1-position of the terminal sugar of an oligosaccharide with an alkyl group and sulfating at least 14.3 % of the remaining hydroxyl groups of the sugar mo...
|
|
WO/1992/002525A1 |
A glucofuranose derivative substituted at the 3,5,6- or 3,6-positions with a radical that provides an anionic charge at physiological pH values is disclosed, as are pharmaceutical compositions, and methods of making and using the same. T...
|
|
WO/1992/002528A1 |
Novel reagents useful in a variety of biochemical and chemical contexts, including nucleic hybridization assays and chemical phosphorylation of hydroxyl-containing compounds. The reagents are particularly useful for introducing cleavable...
|
|
WO/1992/000984A1 |
Disclosed are substances with surface-active properties obtained by reacting alkdienyl glycosides with sulphuring agents, followed by neutralization and hydrolysis of the reaction products with aqueous bases.
|
|
WO/1991/016332A1 |
A 4,6-O-hydroxyphosphorylglucosamine derivative of general formula (I) and a pharmaceutically acceptable salt thereof, wherein R1 and R2 represent each hydrogen or hydroxyl; one of R3 and R4 represents -OCO(CH2)nCH3, -CH2(CH2)nCH3or -O-C...
|
|
WO/1991/015496A1 |
An essentially pure substance has a structure of a Nod factor or one of its analogues. The Nod factor is characterized by the fact that its biosynthesis is controlled by at least one nodulation gene (nodA,B,C) common to the Rhizobiaceae,...
|
|
WO/1991/009604A1 |
L'invention concerne une composition pharmaceutique et l'utilisation d'un composé de formule (I): (OH)6-p-(C4+nH5+mO)-(OPO3H2)p, où n=1, 2 ou 3, m=1, 2, ou 3, p=1, 2 ou 3, pour la préparation d'un médicament permettant de prévenir, ...
|
|
WO/1991/001134A1 |
Non-toxic lipid A derivatives are useful for preventing the detrimental effects of Gram-negative endotoxin and for stimulating the immune systems of animals.
|
|
WO/1990/012561A1 |
A method of treating and/or preventing alopecia (baldness, deficient hair growth) comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of a sulfated mono-, di- or oligosaccharide or ...
|
|
WO/1990/012580A1 |
Novel fractions comprising oligosaccharides having 6 to 8 saccharide units and molecular weights between 1,000 and 2,000 and a sulfur content of less than 9 weight percent, are obtained by depolymerizing heparin or heparan sulfate and fr...
|
|
WO/1990/011823A1 |
A surfactant containing at least one lysophospholipid represented by general formula (1), wherein R1 and R2 each represents a hydrogen atom or an aliphatic acyl residue, provided that one of them is a hydrogen atom and the other is an ac...
|
|
WO/1990/008548A1 |
The invention relates to a liquid preparation for intraocular perfusion to be used in the intraocular operation of an affected site, which contains a substance of formula (I). This preparation causes less troubles of the intraocular tiss...
|
|
WO/1990/006755A1 |
A glycosaminoglycoside (GAG) composition predominantly of tetrasaccharide units derived from heparin/heparan sulfate has enhanced activity in preventing the profileration of smooth muscle cells. This GAG preparation is useful in the trea...
|
|
WO/1990/004607A2 |
The invention comprises: mucopolysaccharides consisting of dermatan sulfate fragments in which the unsulfated uronic acid moieties have been opened, by oxidation of the C(2)-C(3) bonds with periodic acid, and the process for the preparat...
|
|
WO/1990/004597A1 |
The invention concerns a process for preparing glycoconjugates of phosphoramides of general formula (1) and (1a) in which the sugar is linked to the phosphoramide mustard function or the ifosfamide mustard function preferably in the 1 po...
|
|
WO/1990/003791A1 |
Heparin and low molecular weight derivatives of heparin lacking anticoagulant activity are effective in interfering with the life cycle of HIV. Cells exposed to heparin or its low molecular weight derivatives one hour before or after cha...
|
|
WO/1990/001938A1 |
A method of anti-inflammatory and/or immunosuppressive treatment of an animal or human patient comprises administration to the patient of an effective amount of at least one phosphosugar or derivative thereof, or a phosphosugar-containin...
|
|
WO/1990/002133A1 |
An improved chemical process for preparing the anti-ulcer medication, sucralfate, and a sucralfate-like product. Sucrose is reacted with chlorosulfonic acid in pyridine or picoline. The ammonium salt is then formed and reacted with alumi...
|
|
WO/1990/001501A1 |
There are disclosed oligosaccharide compounds having heparin-like anticomplement activity and reduced anticoagulant activity as compared with heparin on a weight or molar basis. The oligosaccharide compounds have at least 5 and no greate...
|
|
WO/1989/012062A1 |
The invention relates to derivatives having formula (I), wherein R' is a hydrogen atom or an azido group, and R1 is a hydrogen atom or a saturated or unsaturated, optionally substituted hydrocarbonaceous radical having from 5 to 30 carbo...
|
|
WO/1989/007932A1 |
La présente invention se rapporte à l'utilisation d'un saccharide sulfaté ou d'un sel ou d'un complexe d'un tel saccharide comme ingrédient d'une préparation topique servant dans la prophylaxie ou le traitement de maladies ou d'éta...
|
|
WO/1989/005645A1 |
Use of sucralfate for the preparation of a medicament for topical application to the skin or to any non-gastrointestinal, non-oral mucosal surface of an animal or a human, including the lining of body cavities, for the prophylaxis or tre...
|
|
WO/1989/005646A1 |
Use of a sulphated saccharide or a salt or complex thereof for the preparation of a medicament for topical application to the skin or to any non-gastrointestinal, non-oral mucosal surface of an animal or a human, including the lining of ...
|
|
WO/1989/000575A1 |
Compounds of formula (I), wherein each of R1 and R2 is independently selected from the group consisting of halogen, hydroxy, or mono carboxylic acid or R1 and R2 together is a multifunctional carboxylic acid residue which forms a ring wi...
|
|
WO/1989/000574A1 |
Platinum compounds useful in the treatment of cancer are disclosed. Compositions containing these compounds and methods of using the same are also discussed. Platinum compounds of formula (I) and (II) and (III) are disclosed. Composition...
|
|
WO/1989/000047A1 |
Hemorrhoidal compositions containing disaccharide polysulfate-aluminum compounds such as sucralfate, alone or in combination with other hemorrhoidal products, as an agent effective for alleviating the symptoms of anorectal disease when t...
|
|
WO/1988/000951A1 |
Method of producing peracetyl oxazolines from peracetyl saccharides. The method involves reacting the starting material, a peracetyl saccharide, with a reactive compound, such as trifilic acid, to directly produce the peracetyl oxazoline.
|
|
WO/1987/000174A2 |
New saccharides having the formula (I), wherein R'1, R'2, R'3 and R'4 are different or identical and independently represent hydrogen or an optionally substituted acyl group and W, X, Y and Z are identical or different and independently ...
|
|
WO/1986/001406A1 |
Preparations in the form of sucralfate-containing suspensions, characterized by a sucralfate-related content of 1-5% (by weight) xanthane rubber and 1-12.5% (by weight) of at least one peptizer.
|
|
WO/1985/004881A1 |
Compounds of formula (I) wherein R2 and R3 are the same or different and each represent unsubstituted or substituted acyl, and a) R1 represents lower alkyl, aralkyl or the phosphate, pyrophosphate, phosphorylethanolamine or pyrophosphory...
|
|
WO/1984/004526A1 |
Lipid X having formula (I) possesses lipid A activity and is useful as an immunostimulating agent. The compound may be isolated from the cells of certain E. coli mutants defective in phosphatidylglycerol synthesis. Derivatives of lipid X...
|
|
WO/1984/001777A1 |
Process for the organic synthesis of oligosaccharides forming or corresponding to fragments of acid mucopolysaccharides wherein two compounds comprised of or terminated respectively by patterns of galactosamine structure and patterns of ...
|
|
WO/1982/003863A1 |
Disaccharides 1,4(Alpha) having the formula: (FORMULA) with Z representing a nitrogenous functional group, MN representing hydrogen or a sulphate or acetyl group, R is an alkyl radical having 1 to 4 atoms of carbon and A a functional gro...
|
|
WO/1982/001005A1 |
Oligosaccharide which contains 4-8 monosaccharide units and which is characterized in that it contains at least one glucosamine unit which is 3-0 sulfated, and at least one additional glucosamine unit, whereby these units are linked via ...
|
|
WO1982000097A1 |
Certain pharmaceutical compositions containing the sulfite or bisulfite ions in the form of alkali metal, alkaline earth metal, ammonium salts or mixtures thereof for treating several thrombotic conditions.
|
|
WO/1980/001069A1 |
A novel compound, N-(6-deoxy-L-talosyloxyhydroxyphosphinyl)-L-leucyl-L-tryptop
hane, having an activity of inhibiting metal protease of Pseudomonas aeruginosa, and a biochemical process for preparing this compound using bacteria of Strep...
|
|
JP2024510146A |
The invention particularly relates to methods of producing sulfated oligosaccharide derivatives and intermediates thereof. The sulfated oligosaccharide derivatives have the following formula (I), where X and Y are any D- or L-hexose or p...
|
|
JP2024014933A |
The present invention provides compounds for use in the prevention or treatment of joint and bone disorders, such as arthritis and osteoporosis, in mammals. [Solution] Formula (A) [C1] The above-mentioned problems are solved by the compo...
|
|
JP2023553990A |
The present disclosure provides improved properties compared to naturally occurring wild-type MTR kinase polypeptides, including phosphorylating D-ribose and 5'-D-isobutyrylribose to form alpha-D-ribose-1-phosphate. and alpha 5'-D-isobut...
|
|
JP7401882B2 |
[Problem to be Solved] An object of the invention is to provide a method of uniformly and efficiently producing a saccharide having a sulfate group and/or a phosphate group in the molecule, or a compound containing the saccharide. [Solut...
|
|
JP2023541497A |
In the present invention, there is no phosphate group at the C1 position of the reducing end of the lipid A domain, and it is substituted by a hydrophilic moiety at the C6' position of the non-reducing end of the lipid A domain, provided...
|
|
JP7296405B2 |
The present invention is directed to compounds of the formulae I, II and III as shown belowwherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods...
|
|
JP2023507786A |
The present invention provides fucosylation inhibitors during protein expression from mammalian cells. Said inhibitor is derived from rhamnose and acts by inhibition of GDP-mannose 4,6-dehydratase (GMD). The invention further provides me...
|
|
JP2023012498A |
To provide an improved method for enzymatic synthesis of 4'-ethynyl nucleosides and analogs thereof.The present invention involves the use of engineered enzymes in novel enzymatic synthesis of 4'-ethynyl-2'-deoxy nucleoside analogs, incl...
|
|
JP2023011860A |
To provide methods for producing oligosaccharide compositions, and oligosaccharide compositions.The method includes: a) a step of combining one or more kinds of sugars with a catalyst to produce a first product mixture, the first product...
|
|
JP2023500294A |
TECHNICAL FIELD The present invention relates to low-molecular-weight chondroitin sulfate and a method for producing the same. Using high-molecular-weight chondroitin sulfate as a raw material, the low-molecular-weight chondroitin sulfat...
|
|
JP7166450B2 |
A fucosylated chondroitin sulfate oligosaccharide having the structure as shown in J, and further disclosed is a method for preparing the fucosylated chondroitin sulfate oligosaccharide: using a chondroitin sulfate A salt as a raw materi...
|
|
JP2022545101A |
The present disclosure relates to GalNAc moieties comprising at least one GalNAc monomer. The present disclosure also relates to GalNAc-oligonucleotide conjugates comprising a GalNAc portion and an oligonucleotide, eg, saRNA or siRNA, us...
|
|
JP7158096B2 |
Described herein are methods for the production of oligosaccharides, including functionalized oligosaccharides, from one or more sugars, such as one or more monosaccharides, using polymeric and solid-supported catalysts containing acidic...
|
